Lisa Anson, Redx Pharma CEO

With PhII fail, Redx Phar­ma scraps monother­a­py bil­iary can­cer de­vel­op­ment for lead pro­gram

UK biotech Redx Phar­ma’s lead drug has failed a Phase II study for bil­iary tract can­cer, and the re­sults are “not suf­fi­cient” to con­tin­ue de­vel­op­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.